SELLAS Life Sciences Group, Inc (SLS) Stock Price, Chart & Analysis
About SELLAS Life Sciences Group, Inc (SLS)
Healthcare · Biotechnology
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NCM
- CEO
- Dr. Angelos M. Stergiou M.D., ScD h.c.
- Employees
- 13
- IPO year
- 2008
- Market cap
- $2.3B
- EPS (TTM)
- $-0.21
- Book value
- $0.68
- 52-week range
- $1.39 – $15.88
- Beta
- 2.57
- Profit margin
- 0.0%
- Return on equity
- -39.6%